Clinical trials: TACE(Transcatheter Arterial Chemoembolization)
Head and Neck Squamous Cell Carcinoma, Oncolytic Virus
H101 Plus TACE for r/m HNSCC
This study evaluates H101 combined with transarterial chemoembolization (TACE) to enhance local tumor killing and immune activation while minimizing toxicity in r/m HNSCC patients.
- Conditions
- Head and Neck Squamous Cell Carcinoma, Oncolytic Virus, TACE
- Trial name
- NCT07398664
- Testing
- H101, TACE
- Where
- China
- Volunteers
- 20 people
- Sponsor
- West China Hospital
Hepatocellular Carcinoma Non-resectable
TACE Combined With Sorafenib and Tislelizumab for Advanced HCC
This study will evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with sorafenib and tislelizumab in patients with advanced hepatocellullar carcinoma (HCC).
- Trial name
- NCT04599777
- Testing
- TACE combined with sorafenib and tislelizumab
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma
Safety Study of Sorafenib Following Combined Therapy of Radiation and TACE for Liver Cancer
Patients with liver cancer will receive interventional therapy plus radiotherapy. Maintenance Sorafenib will be taken after the completion of radiotherapy.
- Trial name
- NCT00999843
- Testing
- Sorafenib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma, Transarterial Chemoembolization
Effects of Antrodia Cinnamomea on the Hepatoma Patients After Transcatheter Hepatic Artery Chemoembolization
Effects of Antrodia cinnamomea on the hepatoma patients after Transcatheter hepatic artery chemoembolization
- Trial name
- NCT07178093
- Testing
- Antrodia cinnamomea
- Where
- Taiwan
- Volunteers
- 23 people
- Sponsor
- Taichung Tzu Chi Hospital
Hepatocellular Carcinoma, Liver Failure
Liver Stiffness Measurement (LSM) in Predicting Progress of Liver Fibrosis After TACE for Hepatocellular Carcinoma
Objective: To evaluate the efficacy of preoperative liver stiffness measurement(LSM) by FibroScan in predicting the progress of liver fibrosis and prognosis after transcatheter arterial chemoembolization (TACE) in hepatocellular…
- Trial name
- NCT03285867
- Testing
- TACE
- Volunteers
- 200 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Carcinoma, Hepatocellular
A Comparative Study of the Efficacy of Transcatheter Arterial Chemoembolization (TACE) and Transcatheter Arterial Pegylated Interferon Embolization (TAIE) for Liver Cancer
Primary: To compare the efficacy of TACE and TAIE. Secondary: To compare the side effects of TACE and TAIE. The outcome measurements include survival benefit and tumour regression induced by the two therapies.
- Trial name
- NCT00563095
- Testing
- Transcatheter Arterial Chemoembolization (TACE), Transcatheter Arterial Pegylated Interferon Embolization (TAIE)
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Hospital Authority, Hong Kong
Hepatocellular Carcinoma
TACE Plus Recombinant Human Adenovirus for Hepatocellular Carcinoma
The purpose of this study is to determine if TACE plus Recombinant Human Adenovirus Type 5 Injection will improve outcome in patients with advanced hepatocellular carcinoma (HCC) not amenable to surgery or local ablative therapy.
- Trial name
- NCT01869088
- Testing
- Recombinant Human Adenovirus Type 5 Injection, Transartery Chemoembolization
- Where
- China
- Volunteers
- 266 people
- Sponsor
- Sun Yat-sen University
Precision Cell Immunotherapy, Transcatheter Arterial Chemoembolization
Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer
To evaluate the safety and effectiveness of cell therapy using precision cells Combined With TACE in Advanced Liver Cancer. Eligibility: Individuals greater than or equal to 18 years of age and less than or equal to 65 years of…
- Conditions
- Precision Cell Immunotherapy, Transcatheter Arterial Chemoembolization, Advanced Liver Cancer
- Trial name
- NCT02873442
- Testing
- TACE, Precision Cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Ningbo Cancer Hospital
Hepatocellular Carcinoma
TACE Combined With ICIs Plus MTT After 125I Irradiation Stent Placement in HCC With Main PVTT.
Hepatocellular carcinoma (HCC) patients with Vp4 [main trunk] portal vein tumor thrombosis (PVTT) face a significantly poor prognosis, and current treatment options provide limited benefits.
- Trial name
- NCT06669377
- Where
- China
- Volunteers
- 444 people
- Sponsor
- Zhongda Hospital
Hepatocellular Carcinoma, Hepatic Chemotherapy
TACE Combined Surgery for the Resectable Huge HCC
Huge hepatocellular carcinoma (HCC) is defined as a tumor with a maximum diameter greater than 10 cm. With advancements in surgical techniques, hepatectomy can be performed safely in some patients with huge HCC without vascular…
- Conditions
- Hepatocellular Carcinoma, Hepatic Chemotherapy, Liver Cancer, Surgery
- Trial name
- NCT06898398
- Testing
- TACE, Surgery
- Where
- China
- Volunteers
- 326 people
- Sponsor
- Sun Yat-sen University
Precision Cells, Chemotherapy
Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer
Objectives: To evaluate the safety and effectiveness of cell therapy using precision cells to treat Advanced Lung Cancer. Eligibility: Individuals greater than or equal to 18 years of age and less than or equal to 65 years of age…
- Conditions
- Precision Cells, Chemotherapy, Advanced Lung Cancer
- Trial name
- NCT02862587
- Testing
- Chemotherapy, precision cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai International Medical Center
Hepatocellular Carcinoma Non-resectable
Fecal Microbiota Transplantation in Reversing Drug Resistance in Unresectable HCC (TALENP004)
This study aims to evaluate the safety and efficacy of fecal microbiota transplantation (FMT) in reversing drug resistance to the triple therapy regimen in patients with unresectable hepatocellular carcinoma (HCC).
- Trial name
- NCT06643533
- Testing
- Fecal Microbiota Transplantation
- Volunteers
- 15 people
- Sponsor
- Fujian Provincial Hospital
Hepatocellular Carcinoma
Accuracy of Contrast-Enhanced Ultrasound for Hepatocellular Carcinoma Post TACE
The purpose of this research study is to find out if a different type of imaging study called contrast enhanced ultrasound (CEUS) is as good as, or better than CT or MRI in patients diagnosed with hepatocellular carcinoma (HCC)…
- Trial name
- TACE (NCT04569799)
- Testing
- Lumason
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Milton S. Hershey Medical Center
Hepatocellular Carcinoma
TACE Combined With RFA/MV Treatment in Hepatocellular Carcinoma Beyond Milan Criterial
This study was designed to evaluate the effectiveness of radiofrequency /microwave ablation in patients with hepatocellular carcinoma beyond Milan Criteria.
- Trial name
- TACE+RFA (NCT03636620)
- Testing
- Transcatheter arterial chemoembolization, radiofrequency ablation/microwave ablation
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma
Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC
This study will evaluate the role of everolimus in combination with local Transcatheter Arterial Chemoembolization (TACE) procedure in patients with localized unresectable Hepatocellular Carcinoma (HCC).
- Trial name
- TRACER (NCT01379521)
- Testing
- everolimus
- Where
- 5 sites in Hong Kong, Taiwan and 1 more
- Volunteers
- 65 people
- Sponsor
- Novartis Pharmaceuticals
Hepatocellular Carcinoma
Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC
To explore the effects of lenvatinib in combination with tislelizumab with or without TACE in patients with hepatocellular carcinoma on survival, disease progression, and medication safety.
- Trial name
- NCT05842317
- Testing
- Lenvatinib Plus Tislelizumab, Transarterial Chemoembolization(TACE)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College Hospital
Hepatocellular Carcinoma, Face Cancer
Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the 6th most common cancer and the third most frequent cause of cancer death worldwide. Hepatic resection (HR) has been the standard treatment modality for HCC aiming at clinical cure.
- Trial name
- NCT01833299
- Testing
- TACE-Sorafenib group, TACE
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma
Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib
The purpose of this study is to evaluate the safety and efficacy of the combination therapy with Transcatheter Arterial Chemoembolization (TACE) and sorafenib compared to TACE alone in patients with unresectable hepatocellular…
- Conditions
- Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma, Carcinoma, Hepatocellular, Liver Neoplasm
- Trial name
- TACTICS (NCT01217034)
- Testing
- TACE with sorafenib, TACE alone
- Where
- Japan
- Volunteers
- 228 people
- Sponsor
- Kindai University
Hepatocellular Carcinoma, Portal Vein Tumor Thrombosis
Irradiation Stent Placement Plus TACE for HCC and PVTT
The study is a multicenter, randomized (1:1), open-label, parallel-arm, Phase 3 clinical trial to evaluate the efficacy and safety of portal irradiation stent placement plus TACE compared to sorafenib plus TACE in patients with…
- Trial name
- NCT03730675
- Testing
- Portal irradiation stent placement, TACE, Sorafenib
- Where
- China
- Volunteers
- 308 people
- Sponsor
- Zhongda Hospital
Hepatocellular Carcinoma, Liver Cancer
TACE as an Adjuvant Therapy After Radiofrequency Ablation (RFA) for Hepatocellular Carcinoma
The purpose of this study is to prospectively evaluate whether transcatheter arterial chemoembolization (TACE) will improve the outcome of radiofrequency ablation for hepatocellular carcinoma (HCC) or not.
- Trial name
- TACE-RFA (NCT00556803)
- Testing
- radiofrequency ablation, TACE after RFA
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Sun Yat-sen University